--- title: Theramex select CARA Life Sciences Platform to consolidate and digitise regulatory processes description: Generis has announced that Theramex has selected the CARA™ Life Sciences Platform to digitise and streamline their Regulatory Information Management process. image: https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [Theramex select CARA Life Sciences Platform to consolidate and digitise regulatory processes](https://news.lifesciencenewswire.com/newsroom/theramex-select-cara-life-sciences-platform-to-consolidate-and-digitise-regulatory-processes) February 1, 2023 [![Theramex select CARA Life Sciences Platform to consolidate and digitise Regulatory Processes](https://news.lifesciencenewswire.com/hs-fs/hubfs/2bb67b8b-0b67-4be7-86ad-b7d58ce98732-upload_image_here-Theramex-PR.png?width=327&height=327&name=2bb67b8b-0b67-4be7-86ad-b7d58ce98732-upload_image_here-Theramex-PR.png)](https://drive.google.com/file/d/1CfHbZnkzVffrz7Q1ckikDjX7bjfCIH73/view?usp=share_link) [Generis](https://www.generiscorp.com/), creator of the cloud data, content, and business process management platform CARA, today announced that Theramex has selected the CARA™ Life Sciences Platform to digitise and streamline their Regulatory Information Management process. Theramex, headquartered in London, UK, is a global speciality pharmaceutical company which produce women’s health products and operate in more than 80 countries. Theramex were searching for a platform to digitise the manual processes across their R&D landscape with a focus on the data and documents within RIM. With frequent audits from regulatory authorities and changing regulations, compliance was a key motivator, alongside a reduction of error and an increase in efficiency across the board. Steven Niss, Group Information Technology Director at Theramex commented: “We wanted to make sure we selected a partner that is going to be with us for a long time, a dependable partner, with whom we can grow a strong relationship – we believe we can do this with Generis.’ One of the key requirements was full traceability, with teams dispersed globally it is vital to have a safe and a secure way of tracking data, without the risk of something getting lost. The organisation wanted to digitise the manual collection of data and transfer it into a single secure database system, equipped with reporting functionality and the ability to track who did what, and when, to achieve traceability and compliance. After a selection process with several other vendors, the CARA Life Sciences Platform was selected as it offered rich functionality and was the preferred option for end-users. “From an end-user perspective, the CARA Life Sciences Platform was the most intuitive with a great look and feel, we saw the excellent functionality and with simple configurations the platform was perfectly aligned with our processes.” added Steven. The CARA Life Sciences Platform gives Theramex the ability to consolidate all processes onto a unified, integrated system. All enterprise data can be stored and accessed on the platform due to its single, structured information lake, eliminating the need for a series of separate point solutions for each process. With the ‘one-user, one-license’ pricing model, and synergy around implementation and project pricing, Generis offered a great solution for a lower overall cost. About Theramex Theramex is a global, speciality pharmaceutical company based in London, UK. Operating in over 80 countries, the company are committed to supporting the health needs of women through every stage of life, with products focusing on contraception, fertility, menopause, and osteoporosis. Theramex have helped millions of women around the world live better lives, and continue to work on patient-focused, effective solutions that support women of all ages. About Generis Generis is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis’ flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com  ##### Browse more news ## Recent releases #### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) July 6, 2026 Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) #### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) June 16, 2026 New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) #### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) June 16, 2026 Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)